{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:42:20Z","timestamp":1788432140187,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,9,7]],"date-time":"2010-09-07T00:00:00Z","timestamp":1283817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,9,7]],"date-time":"2010-09-07T00:00:00Z","timestamp":1283817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s10637-010-9529-9","type":"journal-article","created":{"date-parts":[[2010,9,6]],"date-time":"2010-09-06T06:44:47Z","timestamp":1283755487000},"page":"299-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors"],"prefix":"10.1007","volume":"30","author":[{"given":"Eduardo","family":"Vilar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Cullell-Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Baselga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,7]]},"reference":[{"key":"9529_CR1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/978-3-540-30880-5_16","volume":"43","author":"G Faircloth","year":"2006","unstructured":"Faircloth G, Cuevas C (2006) Kahalalide F and ES285: potent anticancer agents from marine molluscs. Prog Mol Subcell Biol 43:363\u2013379","journal-title":"Prog Mol Subcell Biol"},{"key":"9529_CR2","unstructured":"Baird R, Clarke P, Workman P (2005) ES-285, a novel marine anticancer agent: Investigation of mechanism of action using gene expression microarrays. AACR Meeting Abstracts 2005 (1):970"},{"issue":"2\u20133","key":"9529_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ejphar.2008.02.011","volume":"584","author":"AM Sanchez","year":"2008","unstructured":"Sanchez AM, Malagarie-Cazenave S, Olea N, Vara D, Cuevas C, Diaz-Laviada I (2008) Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation. Eur J Pharmacol 584(2\u20133):237\u2013245. doi:S0014-2999(08)00158-1","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"9529_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0304-3835(99)00428-0","volume":"152","author":"R Cuadros","year":"2000","unstructured":"Cuadros R, Montejo de Garcini E, Wandosell F, Faircloth G, Fernandez-Sousa JM, Avila J (2000) The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers. Cancer Lett 152(1):23\u201329. doi:S0304-3835(99)00428-0","journal-title":"Cancer Lett"},{"issue":"2","key":"9529_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s10495-006-0573-z","volume":"12","author":"M Salcedo","year":"2007","unstructured":"Salcedo M, Cuevas C, Alonso JL, Otero G, Faircloth G, Fernandez-Sousa JM, Avila J, Wandosell F (2007) The marine sphingolipid-derived compound ES 285 triggers an atypical cell death pathway. Apoptosis 12(2):395\u2013409. doi:10.1007\/s10495-006-0573-z","journal-title":"Apoptosis"},{"issue":"6","key":"9529_CR6","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1158\/1535-7163.MCT-08-1167","volume":"8","author":"RD Baird","year":"2009","unstructured":"Baird RD, Kitzen J, Clarke PA, Planting A, Reade S, Reid A, Welsh L, Lopez Lazaro L, de las Heras B, Judson IR, Kaye SB, Eskens F, Workman P, deBono JS, Verweij J (2009) Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. Mol Cancer Ther 8(6):1430\u20131437. doi:1535-7163.MCT-08-1167","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"9529_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"9529_CR8","first-page":"246","volume":"59","author":"MW Den Brok","year":"2005","unstructured":"Den Brok MW, Nuijen B, Meijer DM, Millan E, Manada C, Beijnen JH (2005) Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCL. PDA J Pharm Sci Technol 59(4):246\u2013257","journal-title":"PDA J Pharm Sci Technol"},{"issue":"1","key":"9529_CR9","first-page":"21","volume":"61","author":"MW Den Brok","year":"2006","unstructured":"Den Brok MW, Nuijen B, Garcia JL, Miranda E, Calvo P, Manada C, Beijnen JH (2006) Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices. Pharmazie 61(1):21\u201324","journal-title":"Pharmazie"},{"issue":"5","key":"9529_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/jms.469","volume":"38","author":"E Stokvis","year":"2003","unstructured":"Stokvis E, Nan-Offeringa L, Rosing H, Lopez-Lazaro L, Acena JL, Miranda E, Lyubimov A, Levine BS, D\u2019Aleo C, Schellens JH, Beijnen JH (2003) Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry. J Mass Spectrom 38(5):548\u2013554. doi:10.1002\/jms.469","journal-title":"J Mass Spectrom"},{"key":"9529_CR11","doi-asserted-by":"publisher","unstructured":"Salazar R, Soria J, Majem M, Ropert S, Garcia M, Armand J, Lopez Lazaro L, Escolar L, de las Heras B (2006) Phase I (3 hour infusion every 3\u00a0weeks) escalating dose study of intravenous ES-285 in patients with advanced malignant solid tumors. 4th International Symposium on Targeted Anticancer Therapies. Ann Oncol 17 (S3):iii49-iii50. doi:10.1093\/annonc\/md1922","DOI":"10.1093\/annonc\/md1922"},{"key":"9529_CR12","unstructured":"Massard C, Majem M, Soria J-C, Salazar R, Deutsch E, Garcia M, Oaknin A, Soto A, de las Heras B, Armand J-P (2007) Phase I (3 hour infusion every 3\u00a0weeks) escalating dose study of intravenous es-285 in patients with advanced malignant solid tumors. AACR Meeting Abstracts (3_Molecular_Targets_Meeting):A4"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9529-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-010-9529-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9529-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9529-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:08:17Z","timestamp":1678511297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-010-9529-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,7]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["9529"],"URL":"https:\/\/doi.org\/10.1007\/s10637-010-9529-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,7]]},"assertion":[{"value":"12 July 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}